Article Impact Level: HIGH Data Quality: STRONG Summary of Cell Reports Medicine, 102824. https://doi.org/10.1016/j.xcrm.2026.102824 Dr. Yeji Lee et al.
Points
- Researchers mapped the human CD4+ T cell epitope repertoire using Lassa virus as an Old World prototype and Junin virus as a New World prototype to find targets for pan-viral vaccines.
- Lassa virus causes severe hemorrhagic symptoms that kill between 5,000 and 10,000 people annually and highlights the urgent clinical need for broad-spectrum vaccine interventions against emerging arenaviruses.
- The study demonstrated that human T cells can successfully cross-react with conserved epitope regions within the same viral lineage but cannot bridge the 45,000-year evolutionary divergence between distinct geographic hemispheres.
- Validation trials using human subjects immunized with experimental glycoprotein complex vaccines and infected murine models confirmed that matching internal components can induce broad intra-lineage protective immunity.
- Scientists concluded that a future universal vaccine should combine both Old World and New World immunogens to direct host T cells against every known infective mammalian arenavirus species.
Summary
This study evaluated the human CD4+ T cell epitope repertoire to identify conserved immunodominant targets capable of driving cross-reactive immune responses against diverse mammarenaviruses. Mammarenaviruses are segmented, single-stranded RNA viruses divided into Old World arenaviruses (OWAs) and New World arenaviruses (NWAs) following an evolutionary divergence approximately 45,000 years ago. Given their pandemic potential and high annual mortality—exemplified by Lassa virus (LASV), which causes 5,000 to 10,000 deaths annually—the investigators sought to map conserved T cell epitope regions (CTERs) to inform next-generation, pan-viral vaccine design.
Using Lassa virus as the prototype OWA and Junin virus as the prototype NWA, the researchers calculated sequence conservation across distinct lineages. The analysis revealed that while CD4+ T cells targeted to OWA epitopes broadly cross-recognized related OWAs like lymphocytic choriomeningitis virus (LCMV) and Lujo virus, they demonstrated no cross-reactivity toward NWAs. Conversely, T cells primed by the Junin virus vaccine or infection cross-recognized other NWA sequences. This confirmation of intra-lineage cross-reactivity was successfully validated in human subjects immunized with an experimental glycoprotein complex (GPC) LASV vaccine, individuals with natural LCMV infections, and murine models administered a stabilized GPC vaccine candidate.
The findings demonstrate that a highly effective pan-mammarenavirus vaccine strategy must incorporate a dual-immunogen formulation containing both an OWA and an NWA component. This combined configuration enables T cells to recognize shared, structurally conserved epitopes across both evolutionary arms, offering a proactive defense mechanism against emerging zoonotic threats. This immunogenetic framework provides an adaptable blueprint for rapid vaccine deployment against similar segmented RNA pathogens, such as the Andes hantavirus strain which recently caused an outbreak resulting in 14 infections and three deaths.
Link to the article: https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00241-7?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666379126002417%3Fshowall%3Dtrue
References
Lee, Y., Siddiqui, L., Tarke, A., Kim, M., Michaelis, T., Macias, M., Phillips, E., Mallal, S., Trevizani, R., Frazier, A., Scheuermann, R. H., Zuniga, A., Zmasek, C., Spurgers, K., Akintunde, G., Stonier, S. W., Gagliardi, T. B., Warfield, K., Li, H., … Sette, A. (2026). Decoding the human CD4+ T cell epitope repertoire for Lassa fever virus reveals T cell-based pan-mammarenavirus vaccine candidates. Cell Reports Medicine, 102824. https://doi.org/10.1016/j.xcrm.2026.102824
